February 21, 2020 / 7:46 PM / 3 months ago

U.S. FDA approves Esperion's cholesterol drug

Feb 21 (Reuters) - The U.S Food and Drug Administration approved Esperion Therapeutics Inc’s cholesterol-lowering drug as an add-on treatment to commonly used statins, the agency said on Friday.

Esperion’s lead drug, Nexletol, is intended for patients with high levels of “bad” low-density lipoprotein (LDL) cholesterol who are at an increased risk of cardiovascular events.

The drug will be priced at around $10 per pill, the company told Reuters. (Reporting by Dania Nadeem and Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below